Exagen (XGN) Expected to Announce Earnings on Tuesday

Key Points

• Exagen is expected to report Q3 2026 results before market open on November 3. Analysts forecast a loss of $0.19 per share on revenue of $18.34 million; the earnings call is scheduled for 8:30 a.m. ET.
• The company exceeded expectations in the prior quarter, reporting a $0.13-per-share loss versus the $0.19 consensus estimate and revenue of $19.94 million versus $17.80 million expected. Analysts project full-year and next-year losses of $0.69 and $0.56 per share, respectively.
• Analyst sentiment is generally positive, with a “Moderate Buy” consensus and a $10.12 target price compared with the stock’s $7.47 opening price. Recent target increases include $11 from TD Cowen and Canaccord Genuity, while an insider recently bought shares and the CEO sold stock to cover tax withholding.

Exagen (NASDAQ:XGN - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.19) per share and revenue of $18.34 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. Exagen had a negative net margin of 26.61% and a negative return on equity of 104.46%. The firm had revenue of $19.94 million during the quarter, compared to the consensus estimate of $17.80 million. On average, analysts expect Exagen to post ($0.69) EPS for the current fiscal year and ($0.56) EPS for the next fiscal year.

Exagen Trading Up 2.8%

Shares of XGN stock opened at $7.47 on Tuesday. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 1.96. Exagen has a 52-week low of $2.59 and a 52-week high of $12.23. The business's fifty day moving average is $7.81 and its 200 day moving average is $4.99.

Analysts Set New Price Targets

XGN has been the topic of a number of research analyst reports. B. Riley Financial started coverage on Exagen in a research note on Friday, September 11th. They issued a "buy" rating and a $12.00 target price on the stock. TD Cowen boosted their price objective on Exagen from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, October 13th. Weiss Ratings restated a "sell (e+)" rating on shares of Exagen in a research report on Friday, August 7th. Canaccord Genuity Group raised their target price on shares of Exagen from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, October 19th. Finally, BTIG Research lifted their target price on shares of Exagen from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Exagen has an average rating of "Moderate Buy" and a consensus target price of $10.12.

Insiders Place Their Bets

In other news, major shareholder Jorey Chernett bought 14,000 shares of Exagen stock in a transaction that occurred on Monday, October 19th. The shares were acquired at an average price of $7.46 per share, with a total value of $104,440.00. Following the completion of the purchase, the insider directly owned 2,618,540 shares in the company, valued at $19,534,308.40. The trade was a 0.54% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John Aballi sold 34,294 shares of the firm's stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the sale, the chief executive officer owned 805,540 shares in the company, valued at $6,339,599.80. The trade was a 4.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.40% of the stock is owned by corporate insiders.

Exagen Company Profile

Exagen Inc is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time.

Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.